Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 12/20 | 0.46 |
| ▸ | DRD2 | P14416 | 11/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 10/20 | 0.45 |
| ▸ | DRD3 | P35462 | 9/20 | 0.45 |
| ▸ | DRD4 | P21917 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489960 | 0.89 | ALDH1A1 (0.66) | ALDH1A1LMNADRD1DRD2HPGD | |
| SCHEMBL27501961 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNADRD1DRD2HPGD | |
| SCHEMBL3850258 | 0.81 | ALDH1A1 (0.53) | ALDH1A1LMNADRD2HPGDKDM4E | |
| Thioxanthene SCHEMBL29398766 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNADRD1DRD2HPGD | |
| Thioxanthene SCHEMBL8717 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNADRD1DRD2HPGD | |
| Thioxanthene SCHEMBL27969071 | 0.80 | ALDH1A1 (0.51) | ALDH1A1LMNADRD1DRD2HPGD | |
| Thioxanthene SCHEMBL28751085 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNADRD1DRD2HPGD | |
| SCHEMBL18311802 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNADRD1DRD2HPGD | |
| Thioxanthene SCHEMBL28542371 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNADRD1DRD2HPGD | |
| Thioxanthene SCHEMBL31106427 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNADRD1DRD2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7060711-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-06-13 | — | — | US | disclosed |
| EP-1438307-B1 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1438307-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | Biofrontera Pharmaceuticals GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1321169-A1 | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament | Biofrontera Pharmaceuticals AG (DE) | 2003-06-25 | — | — | EP | disclosed |
| EP-1306376-A1 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003035646-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
| US-20030022920-A1 | 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist | BIOFRONTERA PHARMACEUTICALS AG (DE) | 2003-01-30 | — | — | US | disclosed |
| EP-1270568-A1 | 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002102797-A1 | 1-METHYL-4-(3-ETHOXY-9H-THIOXANTHENE-9-YLIDENE)-PIPERIDINE AND ITS USE AS 5-HT2B AND/OR H1 ANTAGONIST | BIOFRONTERA AG (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | HTR2B, HTR1B, HTR3B | ALDH1A1 547/4885LMNA 4509/4885DRD1 95/4885 |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | HTR2B, HTR1B, HTR3B | ALDH1A1 547/4885LMNA 4509/4885DRD1 95/4885 |
| US-20030022920-A1 | 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist | HTR2B, HTR1B, HTR1A | ALDH1A1 518/4885LMNA 4239/4885DRD1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.